HighVista Strategies LLC Buys New Shares in Perspective Therapeutics, Inc. (NYSE:CATX)

HighVista Strategies LLC purchased a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 113,550 shares of the company’s stock, valued at approximately $1,132,000. HighVista Strategies LLC owned approximately 0.18% of Perspective Therapeutics at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. WealthPLAN Partners LLC acquired a new stake in shares of Perspective Therapeutics in the second quarter valued at about $1,695,000. WINTON GROUP Ltd bought a new position in Perspective Therapeutics in the second quarter valued at approximately $841,000. Bank of New York Mellon Corp increased its position in shares of Perspective Therapeutics by 214.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after purchasing an additional 93,548 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Finally, ClariVest Asset Management LLC acquired a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at approximately $540,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on CATX. Bank of America initiated coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price on the stock. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Oppenheimer cut their target price on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $19.80.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $13.23 on Monday. Perspective Therapeutics, Inc. has a one year low of $2.20 and a one year high of $19.05. The company has a fifty day moving average of $13.81.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. On average, analysts predict that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.